Aug 11, 2020
Soliton Reports Second Quarter 2020 Results
May 18, 2020
Soliton Announces Pivotal Cellulite Clinical Trial Results to be Presented at AAD Virtual Meeting June 12-14
May 14, 2020
Soliton Reports First Quarter 2020 Results
Apr 08, 2020
Soliton Granted New Key Patent for FDA Cleared RAP Technology
Apr 01, 2020
Soliton Announces New Launch Plan of Next Generation Acoustic Shockwave Product Due to COVID-19
Mar 20, 2020
Lead Investigator Evaluates Next-Step for Soliton Pivotal Cellulite Clinical Data
Mar 09, 2020
Soliton signs Agreement with Global Manufacturer Sanmina
Feb 11, 2020
Soliton Files Special 510(k) with FDA for its Generation II RAP Device
Feb 06, 2020
Soliton Advances Market Launch Preparation; Appoints James Bucher as Senior Sales Consultant
Jan 07, 2020
Soliton Appoints Robert "Joe" Mills as Vice President of Supply Chain
Dec 20, 2019
On-Chip Light Source Produces Versatile Range of Wavelengths
Dec 18, 2019
Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device
Dec 10, 2019
Soliton Appoints Mary Stoll as Senior Director of Clinical Development
Dec 03, 2019
Soliton Initiates Significant Step Towards Commercialization
Nov 21, 2019
Soliton and Emphysys Enter Into a 3-year Development Agreement
Oct 15, 2019
Soliton's FDA Cleared RAP Device is Granted Two Additional Key Patents
Oct 03, 2019
Soliton Announces Tattoo Technology Article Published in Medical Journal and Selected as Editor's Choice
Sep 17, 2019
Soliton Completes Trial Enrollment and Conducts Initial Site Training to Start Keloid Trial
Sep 04, 2019
Soliton Announces IRB Approval for Keloid Trial
Aug 26, 2019
Soliton Engages argodesign in Preparation of Commercial Launch of its RAP Device